#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease

Episode Summary

Executive Summary: This AMA episode connects insulin, ApoB, LDL-C, and LP(a) to ASCVD risk, arguing that hyperinsulinemia worsens cardiovascular risk both by raising ApoB-containing particles and by impairing endothelial function. The hosts emphasize ApoB as the best practical goalpost, while noting LP(a) is largely genetic and that earlier intervention matters because lifetime risk accumulates over time.

Main Topics: ASCVD risk framework: throttle, brake, and time (Priority: 5/5): Peter Atiyah uses a race-car analogy to explain how ASCVD risk is shaped by factors that accelerate disease (throttle) and factors that slow it (brake), with age determining how much time remains before the 'cliff.' ApoB vs LDL-C as risk markers (Priority: 5/5): The episode clarifies that LDL-C measures cholesterol content inside LDL particles, while ApoB better captures the number of atherogenic particles, including LDL, VLDL, and LP(a)-related particles. Hyperinsulinemia as a driver of ASCVD (Priority: 5/5): The discussion explains how insulin resistance and hyperinsulinemia increase ASCVD risk through ApoC3 upregulation, reduced lipoprotein lipase activity, higher triglycerides, and more ApoB-containing particles. Endothelial dysfunction as a second mechanism (Priority: 4/5): Beyond lipoprotein changes, insulin may directly impair endothelial function, making it easier for ApoB particles to enter and be retained in the arterial wall. LP(a) and inherited residual risk (Priority: 4/5): LP(a) is presented as a largely nonmodifiable, genetically determined contributor to baseline ASCVD risk that acts like a constant throttle setting. Lifetime vs 10-year risk (Priority: 4/5): The hosts stress that focusing only on short-term risk can miss the cumulative benefit of early prevention, especially for younger people who may appear healthy now but still carry long-term risk.

Key Arguments: ASCVD risk is best understood as the balance between factors that accelerate disease and factors that slow it, with age determining how much time remains to intervene. ApoB is the preferred clinical target because it reflects the number of atherogenic particles, not just the cholesterol they carry. LDL-C is still useful, but it is an imperfect proxy because it measures cholesterol mass rather than particle number. Hyperinsulinemia is associated with worse ASCVD outcomes, especially in type 2 diabetes, and likely contributes through multiple mechanisms. One major mechanism is ApoC3-mediated inhibition of lipoprotein lipase, which raises triglycerides and increases ApoB-containing remnant and LDL particles. A second mechanism is endothelial dysfunction, which may allow ApoB particles to more easily enter and remain in the arterial wall. LP(a) is largely inherited and should be treated as baseline residual risk rather than something lifestyle can meaningfully eliminate. Earlier intervention matters because lowering ApoB sooner gives more time to reduce cumulative exposure and slow progression toward ASCVD.

Data Points: ASCVD burden: #1 leading killer - Described as the number one leading killer in the US and worldwide for men and women. Type 2 diabetes and ASCVD risk: about twice as likely / 50% to 2x likely - The hosts state that people with type 2 diabetes are roughly 1.5x to 2x more likely to develop ASCVD and all-cause mortality. AMA episode number: 43 - The conversation is introduced as Ask Me Anything episode number 43. Referenced prior episode on ApoB: 185 - Alan Snyderman episode cited as a deeper discussion of ApoB. Referenced prior episode on insulin: 140 - Gerard Shulman episode cited as a deeper discussion of insulin and hyperinsulinemia. Referenced prior episode on LP(a): 210 - Ben Waugh episode cited as a deeper discussion of LP(a). Referenced prior AMA: 34 - Mentioned as a prior episode covering what causes ASCVD.

Pivotal Quotes: "the number one leading killer in the US worldwide for men, for women" — Peter Atiyah: Introduces why ASCVD risk is the central topic of the episode. "ApoB is the better predictor of risk because it captures not only the concentration of LDL ... but also because it includes the other atherogenic particles" — Nick Stenson: Explains why ApoB is preferred over LDL-C as a clinical risk marker. "hyperinsulinemia is a risk factor that also increases both directly and indirectly the risk of ASCVD" — Peter Atiyah: Summarizes the episode’s core mechanistic claim about insulin and cardiovascular risk.

Implications: Listeners should think beyond glucose alone and assess ApoB, LP(a), blood pressure, smoking, and insulin resistance early. For clinicians, the episode reinforces ApoB-centered prevention and lifetime-risk thinking rather than relying only on short-term risk estimates.